IL-6 Inhibitor · Humanised IgG1 mAb · Anti-IL-6 Receptor

Tocilizumab Actemra®

A humanised IgG1 monoclonal antibody targeting both the soluble and membrane-bound forms of the interleukin-6 receptor (IL-6R). By blocking IL-6 signalling at the receptor level, tocilizumab suppresses the acute-phase response, joint inflammation and systemic inflammatory cascades. Approved for RA, systemic and polyarticular JIA, giant cell arteritis and cytokine release syndrome. The SHIKARI® tocilizumab portfolio covers drug-level quantification, qualitative ADA screening and quantitative ADA titre measurement for complete TDM and immunogenicity research.

SHIKARI® Kits

Tests per kit

Analytical Domains

RUO

Research Use Only

Request a Quote SHIKARI® Catalogue ↗

Footprints leading across snow, the official Tocilizumab Trace & Catch visual — TRACE & CATCH · TOCILIZUMAB

Scientific Background

Why Tocilizumab is relevant to biological-drug monitoring research

Tocilizumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗

Mechanism

Molecular Target & Structure

Tocilizumab is a humanised IgG1 monoclonal antibody that binds both soluble and membrane-bound interleukin-6 receptor (IL-6R), inhibiting IL-6-mediated signalling. Source ↗

Indications

Approved Indications

EMA-authorised uses include rheumatoid arthritis, systemic and polyarticular juvenile idiopathic arthritis, giant-cell arteritis, cytokine-release syndrome and selected severe COVID-19 settings under the approved product information. EMA source ↗

Published Evidence

Selected Tocilizumab Concentration Evidence

Published research provides study-specific concentration references for IL-6 receptor blockade and precision-dosing work:

RA · associated with biochemical IL-6R blockade>1 mg/L ↗

Precision-dosing study target5 mg/L ↗

Research-associated ranges, not universal treatment cut-offs. Values vary by endpoint, timing, assay method and population. This page is for RUO product information and does not provide clinical guidance.

SHIKARI® Kit Portfolio

Three kits. Drug levels, qualitative screening and quantitative ADA profiling.

Request full panel ↗

Drug Levels Kit

SHIKARI® Q-TOC

Quantitative Determination of Tocilizumab (Actemra®) ELISA

REF: TOC-FD-ACT

Sandwich ELISA for the quantitative measurement of free tocilizumab drug concentration in serum and plasma. Calibrated against certified reference standards. 70-minute total assay time. Suitable for trough-level monitoring across IV and SC dosing regimens, pharmacokinetic profiling in RA and JIA populations, and dose optimisation research.

Representative Standard Curve

96 Tests/kit

2–8°C Storage

10–30°C Shipment

Sandwich ELISASerum / Plasma

Full technical datasheet on matriksbiotek.com ↗

Qualitative ADA Kit

SHIKARI® S-ATOC

Qualitative Determination of Antibodies to Tocilizumab ELISA

REF: TOC-QLS-ACT

Bridging ELISA for the qualitative detection of anti-tocilizumab antibodies (ADA) in serum and plasma. Validated positive and negative cut-off controls included for definitive classification. 140-minute total assay time. Suitable for immunogenicity screening in RA, sJIA, pJIA and GCA cohorts, and as a first-line screen ahead of quantitative ADA titre confirmation.

96 Tests/kit

2–8°C Storage

10–30°C Shipment

Bridging ELISASerum / Plasma

Full technical datasheet on matriksbiotek.com ↗

Quantitative ADA Kit

SHIKARI® S-ATOC

Quantitative Determination of Antibodies to Tocilizumab ELISA

REF: TOC-QNS-ACT

Calibrated bridging ELISA for the quantitative determination of anti-tocilizumab ADA titre in serum and plasma. Confirmation reagent included for drug interference assessment. 140-minute total assay time. Suitable for longitudinal ADA titre monitoring, dose-response correlation and comparative immunogenicity research across biologic classes in rheumatology and paediatric populations.

Representative Standard Curve

96 Tests/kit

2–8°C Storage

10–30°C Shipment

Bridging ELISACalibrated

Full technical datasheet on matriksbiotek.com ↗

Technical Reference

Kit Specifications at a Glance

Kit Name	Catalog Code	Type	Analyte	ELISA Format	Tests	Storage
SHIKARI® Q-TOC	TOC-FD-ACT	Drug Levels Kit	Free tocilizumab concentration	Sandwich ELISA	96	2–8°C
SHIKARI® S-ATOC (Qualitative)	TOC-QLS-ACT	Qualitative ADA Kit	Qualitative anti-tocilizumab ADA	Bridging ELISA	96	2–8°C
SHIKARI® S-ATOC (Quantitative)	TOC-QNS-ACT	Quantitative ADA Kit	Anti-tocilizumab ADA titre	Bridging ELISA	96	2–8°C

Kit Selection Guide

Which kit fits your research question?

Tocilizumab TDM differs from anti-TNF monitoring in that receptor saturation — not just drug exposure — is the pharmacodynamic endpoint. Selecting the right assay format is critical.

📏

I need to measure tocilizumab drug levels

Use TOC-FD-ACT for quantitative tocilizumab trough measurement. 70-minute sandwich ELISA — suitable for both IV and SC dosing regimens, and for paediatric (sJIA/pJIA) weight-dosed populations.

🔍

I need to screen for anti-tocilizumab antibodies

Use TOC-QLS-ACT (qualitative bridging ELISA) with validated cut-off controls. Rapid immunogenicity screening for RA, sJIA, pJIA and GCA cohorts. Use as the first-tier assay in a tiered testing approach.

📈

I need to quantify ADA titre longitudinally

Use TOC-QNS-ACT (calibrated bridging ELISA) for ADA titre measurement. Confirmation reagent included. Suitable for kinetic ADA profiling and correlating ADA titre with drug levels and clinical outcomes.

⚖️

I need paired drug-level and ADA data

Run TOC-FD-ACT with TOC-QLS-ACT or TOC-QNS-ACT when a research protocol requires paired drug-concentration and immunogenicity data. Associations should be analysed within the study design and must not be treated as diagnostic conclusions.

👶

I need to monitor tocilizumab in JIA patients

Use TOC-FD-ACT to quantify tocilizumab concentrations in JIA research cohorts. Combine it with TOC-QLS-ACT when immunogenicity is part of the research question; interpret exposure data by age, weight, regimen, sampling time and assay.

🔬

I need a complete tocilizumab TDM research panel

All three kits together cover drug levels, qualitative ADA screening and quantitative titre profiling — the complete evidence package for a TDM-guided optimisation study. Contact us for panel pricing and validation support documentation.

Tocilizumab Actemra®

Why Tocilizumab is relevant to biological-drug monitoring research

Molecular Target & Structure

Approved Indications

Selected Tocilizumab Concentration Evidence

Three kits. Drug levels, qualitative screening and quantitative ADA profiling.

Kit Specifications at a Glance

Which kit fits your research question?

Tocilizumab Literature and Product-Use Records

Ready to order, or need technical guidance?

Review your quote list